相关实验视频
Updated: Mar 15, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
数字驱动的医生和药剂师协作模型对初级医疗保健中的糖尿病的影响:集群随机试验
Jie Xiao1,2, Qing Wang1,2, Shenglan Tan1,2
1Department of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China.
Journal of medical Internet research
|March 13, 2026
概括
数字医生和药剂师的合作改善了资源不足地区的长期2型糖尿病 (T2D) 管理. 这种模式降低了HbA1c和心血管风险,提高了患者的护理和降低了成本.
科学领域:
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
- 数字健康数字健康
背景情况:
- 医生和药剂师合作诊所对2型糖尿病 (T2D) 患者显示了短期的好处.
- 在初级保健和资源不足的环境中,长期有效性仍未得到充分探索.
研究的目的:
- 评估T2D管理的新型,数字驱动的医生和药剂师合作模式的长期有效性和成本效益.
- 在缺乏资源的初级医疗保健机构中评估该模型.
主要方法:
- 在6个中国初级医疗保健机构进行了为期12个月的集群随机对照试验.
- 干预包括例行医生护理以及通过面对面访问和移动健康的药剂师干预.
- 与对照组相比,干预组接受了4次访问和每两周一次的远程教育.
主要成果:
- 在干预组中,血红蛋白A1c (HbA1c) 和10年动脉样硬化心血管风险显著降低.
- 在禁食血糖,血压和脂质资料中观察到的改善.
- 降低了与糖尿病相关的成本,提高了患者的满意度.
结论:
- 数字医生-药剂师协作模式提高了资源不足地区的长期T2D管理质量和效率.
- 这种方法可以降低医疗费用并改善结果,特别是对于中心肥胖或心血管风险高的患者.
相关概念视频
Primary Healthcare Services
2.6K
Primary care promotes wellness and prevents disease. This care includes health promotion, education, protection (such as immunizations), early disease screening, and environmental considerations. Settings providing this type of healthcare include physician offices, public health clinics, school nursing, and community health nursing.
In 1978, international leaders convened in Alma-Ata, Kazakhstan, for what would be a pivotal event in global health. The Alma-Ata Declaration was the first to call...
In 1978, international leaders convened in Alma-Ata, Kazakhstan, for what would be a pivotal event in global health. The Alma-Ata Declaration was the first to call...
2.6K
Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Pharmacokinetic–Pharmacodynamic Relationship: Model Components
92
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
92
Pharmacodynamic Models: Overview
68
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
68
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
59
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
302
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
302

